Genprex
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 2009-01-01
- Employees
- 26
- Market Cap
- $1.8M
- Website
- http://www.genprex.com
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
Phase 1
Recruiting
- Conditions
- Small Cell Lung Cancer Extensive Stage
- Interventions
- Biological: quaratusugene ozeplasmidBiological: atezolizumab
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Genprex, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT05703971
- Locations
- ๐บ๐ธ
Rocky Mountain Cancer Centers, LLP, Lone Tree, Colorado, United States
๐บ๐ธWashington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, United States
๐บ๐ธNorthwest Cancer Specialists, P.C., Vancouver, Washington, United States
Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer
Phase 1
Terminated
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Drug: Investigator's Treatment of Choice
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Genprex, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT05062980
- Locations
- ๐บ๐ธ
Moffitt Cancer Center - Magnolia Campus, Tampa, Florida, United States
๐บ๐ธOchsner Clinic Foundation, New Orleans, Louisiana, United States
๐บ๐ธWashington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, United States
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Phase 1
Recruiting
- Conditions
- Carcinoma, Non-Small Cell Lung
- Interventions
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Genprex, Inc.
- Target Recruit Count
- 158
- Registration Number
- NCT04486833
- Locations
- ๐บ๐ธ
Valkyrie Clinical Trials, Los Angeles, California, United States
๐บ๐ธRocky Mountain Cancer Centers, Lone Tree, Colorado, United States
๐บ๐ธCarle Cancer Institute, Urbana, Illinois, United States
TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer
Phase 1
Terminated
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Genprex, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT01455389
- Locations
- ๐บ๐ธ
UT MD Anderson Cancer Center, Houston, Texas, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath